Loading company…
Tsingke Biotechnology develops synthetic genomics products, life science equipment and materials, and CDMO and CRO services.
Founded in 2017 and based in Beijing, Tsingke Biotechnology develops synthetic genomics products and services, life science equipment and materials, and CDMO and CRO services. Its facilities include production workshops and an R&D center covering 12,000 square meters. As of September 2021, it had 1,700 employees and 122 patents, including 53 invention patents. Its customers span China, the US, and German. In January 2026, it closed venture funding from New Third Board (NEEQ), under ticker "874813". The company reports about 200 million base syntheses and has developed equipment for gene synthesis.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in